MedTrace Logo

Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia

NCT04679350 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2024-02-15

No results posted yet for this study

Summary

To explore the efficacy and confirm the safety of the concomitant administration of the standard of care and hzVSF-v13 in patients with COVID-19 infection

Conditions

Interventions

DRUG

hzVSF-v13

Drug: hzVSF-v13 Dosage form: hzVSF-v13 40mg/mL in a 5mL vial Frequency: Dose at Day 1, 3, 7 Other names: a humanized monoclonal antibody (mAb)

DRUG

Placebo (Normal saline solution)

Dosage form: 0.9% NaCl solution Frequency: Dose at Day 1, 3, 7

Sponsors & Collaborators

  • ImmuneMed, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-18
Primary Completion
2022-11-30
Completion
2022-12-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04679350 on ClinicalTrials.gov